EUVIMEDEUVIMED entdecken
BeobachtungsstudieVergleichsstudieMultizentrische StudieOpen Access

Comparative Effectiveness of Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter 2 Inhibitors, Dipeptidyl Peptidase-4 Inhibitors, and Sulfonylureas for Sight-Threatening Diabetic Retinopathy

Andrew J Barkmeier, Jeph Herrin, Kavya Sindhu Swarna, Yihong Deng, Eric C Polley, Guillermo E Umpierrez, Rodolfo J Galindo, Joseph S Ross, Mindy M Mickelson, Rozalina G McCoy

Ophthalmology Retina · 2024-10 · 8 (10) · 943-952

DOI: 10.1016/j.oret.2024.05.003 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Ophthalmology Retina, 2024-10. Verfasst von Andrew J Barkmeier und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Mayo Clinic, Rochester, Minnesota. Electronic address: barkmeier.andrew@mayo.edu. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Diabetic Retinopathy, Dipeptidyl-Peptidase IV Inhibitors, Glucagon-Like Peptide-1 Receptor Agonists. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, Patient-Centered Outcomes Research Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: To investigate whether the choice of glucose-lowering agent for type 2 diabetes (T2D) impacts a patient's risk of developing sight-threatening diabetic retinopathy complications. DESIGN: Retrospective observational database study emulating an idealized target trial. SUBJECTS: Adult (≥21 years) enrollees in United States commercial, Medicare Advantage, and Medicare fee-for-service plans from January 1, 2014, to December 31, 2021, with T2D and moderate cardiovascular disease (CVD) risk who had no baseline history of advanced diabetic retinal complications, initiating treatment with glucagon-like peptide-1 receptor agonists (GLP-1 RA), sodium-glucose cotransporter 2 inhibitors (SGLT2i), dipeptidyl peptidase-4 inhibitors (DPP-4i), and sulfonylureas. METHODS: We used inverse propensity scoring weights in time-to-event Cox proportional hazards models. MAIN OUTCOME MEASURES: Treatment for either diabetic macular edema or proliferative diabetic retinopathy. RESULTS: The final study population included 371 698 patients, of whom 42 265 initiated GLP-1 RA, 53 476 initiated SGLT2i, 78 444 initiated DPP-4i, and 197 513 initiated sulfonylurea agents. The probability of treatment for sight-threatening retinopathy within 2 and 5 years was 0.3% and 0.7% for patients initiating SGLT2i (median follow-up 830 [interquartile range (IQR), 343-1401] days), 0.4% and 1.0% for GLP-1 RA (669 [IQR, 256-1167] days), 0.4% and 0.9% for DPP-4i (1263 [IQR, 688-1938] days), and 0.5% and 1.2% for sulfonylurea (1223 [IQR, 662-1879] days). Sodium-glucose cotransporter 2 inhibitors use was associated with a lower risk of treatment for sight-threatening retinopathy compared with all other medication classes, including GLP-1 RA (hazard ratio [HR], 0.73; 95% confidence interval [CI], 0.55-0.97), DPP-4i (HR, 0.79; 95% CI, 0.64-0.97), and sulfonylurea (HR, 0.61; 95% CI, 0.50-0.74). Glucagon-like peptide-1 receptor agonists use was associated with a similar risk of sight-threatening retinopathy as DPP-4i (HR, 1.07; 95% CI, 0.85-1.35) and sulfonylurea (HR, 0.83; 95% CI, 0.67-1.03). CONCLUSIONS: Sodium-glucose cotransporter 2 inhibitors use was associated with a lower risk of sight-threatening diabetic retinopathy among adults with T2D and moderate CVD risk compared with other glucose-lowering therapies. Glucagon-like peptide-1 receptor agonists do not confer increased retinal risk, relative to DPP-4i and sulfonylurea medications. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Diabetic RetinopathyDipeptidyl-Peptidase IV InhibitorsGlucagon-Like Peptide-1 Receptor AgonistsSodium-Glucose Transporter 2 InhibitorsSulfonylurea CompoundsFemaleHumansMaleBlood GlucoseFollow-Up StudiesHypoglycemic AgentsRetrospective StudiesTreatment OutcomeUnited StatesAdult

Stichwörter der Autor:innen

Diabetic macular edemaDiabetic retinopathyGLP-1 RAProliferative diabetic retinopathySGLT2i

Substanzen

Blood GlucoseDipeptidyl-Peptidase IV InhibitorsGlucagon-Like Peptide-1 Receptor AgonistsHypoglycemic AgentsSodium-Glucose Transporter 2 InhibitorsSulfonylurea Compounds

Autor:innen und Institutionen

  • Department of Ophthalmology, Mayo Clinic, Rochester, Minnesota. Electronic address: barkmeier.andrew@mayo.edu.
  • Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut.
  • Mayo Clinic Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Rochester, Minnesota; OptumLabs, Eden Prairie, Minnesota.
  • Department of Public Health Sciences, the University of Chicago, Chicago, Illinois.
  • Division of Endocrinology, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia.
  • Division of Endocrinology, Department of Medicine, University of Miami Miller School of Medicine, Miami, Florida.

Förderung

  • NIDDK NIH HHS
  • Patient-Centered Outcomes Research Institute

Zitieren

APA

Barkmeier, A. J., Herrin, J., Swarna, K. S., Deng, Y., Polley, E. C., Umpierrez, G. E., Galindo, R. J., Ross, J. S., Mickelson, M. M., & McCoy, R. G. (2024). Comparative Effectiveness of Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter 2 Inhibitors, Dipeptidyl Peptidase-4 Inhibitors, and Sulfonylureas for Sight-Threatening Diabetic Retinopathy. Ophthalmology Retina, 8(10), 943-952. https://doi.org/10.1016/j.oret.2024.05.003

Vancouver

Barkmeier AJ, Herrin J, Swarna KS, Deng Y, Polley EC, Umpierrez GE, et al. Comparative Effectiveness of Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter 2 Inhibitors, Dipeptidyl Peptidase-4 Inhibitors, and Sulfonylureas for Sight-Threatening Diabetic Retinopathy. Ophthalmology Retina. 2024;8(10):943-952. doi:10.1016/j.oret.2024.05.003

BibTeX
@article{Barkmeier2024,
  author = {Barkmeier, Andrew J and Herrin, Jeph and Swarna, Kavya Sindhu and Deng, Yihong and Polley, Eric C and Umpierrez, Guillermo E and Galindo, Rodolfo J and Ross, Joseph S and Mickelson, Mindy M and McCoy, Rozalina G},
  title = {Comparative Effectiveness of Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter 2 Inhibitors, Dipeptidyl Peptidase-4 Inhibitors, and Sulfonylureas for Sight-Threatening Diabetic Retinopathy},
  journal = {Ophthalmology Retina},
  year = {2024},
  volume = {8},
  number = {10},
  pages = {943--952},
  doi = {10.1016/j.oret.2024.05.003}
}
Kostenlos starten →